GlassScriptPhysician profile
Danielle N Hansen
NPI 1407512601
$1,254.76
in general payments reported to CMS, 2019-2025
11 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $293 · 2023: $155 · 2024: $400 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879 · Education: $83.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.64 |
| Education | $83.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $254.24 | 2022-2025 | Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $180.72 | 2022-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $158.04 | 2024-2025 | Uzedy |
| Indivior INC. | $156.72 | 2024-2025 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $116.90 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $113.20 | 2024-2025 | Vivitrol |
| Janssen Pharmaceuticals, INC | $97.19 | 2022-2023 | Invega Sustenna, Invega Trinza |
| Braeburn INC. | $65.14 | 2024-2025 | Brixadi |
| Lundbeck LLC | $51.00 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $45.03 | 2023 | Ingrezza |
| Harmony Biosciences LLC | $16.58 | 2023 | Wakix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.